Body iron disorders have been reported after myeloablative conditioning in patients undergoing hematopoietic stem cell transplantation (HSCT). There is a concern that labile plasma iron (LPI), the redox-active form of iron, can be involved in the occurrence of toxicity and other complications commonly observed in the early post-HSCT period. In order to better understand the LPI kinetics and its determinants and implications, we undertook sequential LPI determinations before and after conditioning until engraftment in 25 auto-HSCT patients. Increased LPI was present in only 5 patients before starting conditioning. Shortly after conditioning, LPI levels were increased in 23 patients, with peak at day 0, returning to normal range upon engraftment in 21 patients. Overall, LPI levels correlated weakly with serum ferritin and more strongly with transferrin saturation; however, both parameters were apparently not applicable as surrogate markers for increased LPI. Although this was a small cohort, logistic regression suggested that baseline LPI levels could predict occurrence of grade III or IV toxicity. In conclusion, LPI kinetics is influenced by aplasia following conditioning and engraftment. Measuring LPI before starting conditioning can offer an opportunity to predict toxicity and, perhaps, the need for chelation therapy.

Keywords:
Labile plasma iron, Hematopoietic stem cell transplantation, Iron overload, Toxicity
1.
Majhail NS, Lazarus HM, Burns LJ: Iron overload in hematopoietic cell transplantation. Bone Marrow Transplant 2008;41:997-1003.
2.
Evens AM, Mehta J, Gordon LI: Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress. Bone Marrow Transplant 2004;34:561-571.
3.
Pullarkat V, Blanchard S, Tegtmeier B, Dagis A, Patane K, Ito J, Forman SJ: Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2008;42:799-805.
4.
Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI: Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003;102:2670-2677.
5.
Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P: LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005;18:277-287.
6.
Rachmilewitz EA, Weizer-Stern O, Adamsky K, Amariglio N, Rechavi G, Breda L, Rivella S, Cabantchik ZI: Role of iron in inducing oxidative stress in thalassemia: can it be prevented by inhibition of absorption and by antioxidants? Ann NY Acad Sci 2005;1054:118-123.
7.
Carbonell T, Rama R: Iron, oxidative stress and early neurological deterioration in ischemic stroke. Curr Med Chem 2007;14:857-874.
8.
Sulieman M, Asleh R, Cabantchik ZI, Breuer W, Aronson D, Suleiman A, Miller-Lotan R, Hammerman H, Levy AP: Serum chelatable redox-active iron is an independent predictor of mortality after myocardial infarction in individuals with diabetes. Diabetes Care 2004;27:2730-2732.
9.
Kukongviriyapan V, Somparn N, Senggunprai L, Prawan A, Kukongviriyapan U, Jetsrisuparb A: Endothelial dysfunction and oxidant status in pediatric patients with hemoglobin E-beta thalassemia. Pediatr Cardiol 2008;29:130-135.
10.
Ozment CP, Turi JL: Iron overload following red blood cell transfusion and its impact on disease severity. Biochim Biophys Acta 2009;1790:694-701.
11.
Li H, Rybicki AC, Suzuka SM, von Bonsdorff L, Breuer W, Hall CB, Cabantchik ZI, Bouhassira EE, Fabry ME, Ginzburg YZ: Transferrin therapy ameliorates disease in beta-thalassemic mice. Nat Med 2010;16:177-180.
12.
Gattermann N, Finelli C, Della Porta M, Fenaux P, Stadler M, Guerci-Bresler A, Schmid M, Taylor K, Vassilieff D, Habr D, Marcellari A, Roubert B, Rose C: Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica 2012;97:1364-1371.
13.
Daar S, Pathare A, Nick H, Kriemler-Krahn U, Hmissi A, Habr D, Taher A: Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur J Haematol 2009;82:454-457.
14.
Zanninelli G, Breuer W, Cabantchik ZI: Daily labile plasma iron as an indicator of chelator activity in thalassaemia major patients. Br J Haematol 2009;147:744-751.
15.
Sakiyama M, Kami M, Hori A, Imataki O, Hamaki T, Murashige N, Kobayashi K, Kishi Y, Kojima R, Kim SW, Kusumi E, Yuji K, Miyakoshi S, Mori S, Tanosaki R, Taniguchi S, Takaue Y: Regimen-related toxicity following reduced-intensity stem-cell transplantation (RIST): comparison between Seattle criteria and National Cancer Center Common Toxicity criteria (NCI-CTC) version 2.0. Bone Marrow Transplant 2004;34:787-794.
16.
Bradley SJ, Gosriwitana I, Srichairatanakool S, Hider RC, Porter JB: Non-transferrin-bound iron induced by myeloablative chemotherapy. Br J Haematol 1997;99:337-343.
17.
Sahlstedt L, von Bonsdorff L, Ebeling F, Parkkinen J, Juvonen E, Ruutu T: Non-transferrin-bound iron in haematological patients during chemotherapy and conditioning for autologous stem cell transplantation. Eur J Haemtaol 2009;83:455-459.
18.
Dürken M, Herrnring C, Finckh B, Nagel S, Nielsen P, Fischer R, Berger HM, Moison RM, Pichlmeier U, Kohlschütter B, Zander AR, Kohlschütter A: Impaired plasma antioxidative defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation. Free Radic Biol Med 2000;28:887-894.
19.
Cetin T, Arpaci F, Yilmaz MI, Saglam K, Ozturk B, Komurcu S, Gunay M, Ozet A, Akay C, Kilic S, Ulutin C: Oxidative stress in patients undergoing high-dose chemotherapy plus peripheral blood stem cell transplantation. Biol Trace Elem Res 2004;97:237-247.
20.
Weijl NI, Elsendoorn TJ, Moison RM, Lentjes EG, Brand R, Berger HM, Osanto S: Non-protein bound iron release during chemotherapy in cancer patients. Clin Sci 2004;106:475-484.
21.
von Bonsdorff L, Lindeberg E, Sahlstedt L, Lehto J, Parkkinen J: Bleomycin-detectable iron assay for non-transferrin-bound iron in hematologic malignancies. Clin Chem 2002;48:307-314.
22.
Harrison P, Marwah SS, Hughes RT, Bareford D: Non-transferrin bound iron and neutropenia after cytotoxic chemotherapy. J Clin Pathol 1994;47:350-352.
23.
Armand P, Kim HT, Rhodes J, Sainvil MM, Cutler C, Ho VT, Koreth J, Alyea EP, Hearsey D, Neufeld EJ, Fleming MD, Steen H, Anderson D, Kwong RY, Soiffer RJ, Antin JH: Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant 2011;17:852-860.
24.
Dürken M, Nielsen P, Knobel S, Finckh B, Herrnring C, Dresow B, Kohlschütter B, Stockschläder M, Krüger WH, Kohlschütter A, Zander AR: Nontransferrin-bound iron in serum of patients receiving bone marrow transplants. Free Radic Biol Med 1997;22:1159-1163.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.